Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic SyndromeYang Jo Chung 1, Ghanwa Khawaja 1, Karen M. Wolcott 2, Peter D. Aplan 1
1Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 2LGI Flow Cytometry Core Facility, Center for Cancer Research, National Cancer Institute, National Institutes of Health
We describe the use of hematopoietic stem cell transplantation (HSCT) to assess the malignant potential of genetically engineered hematopoietic cells. HSCT is useful for evaluating various malignant hematopoietic cells in vivo as well as generating a large cohort of mice with myelodysplastic syndromes (MDS) or leukemia to evaluate novel therapies.
